Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.39 |
| ▸ | MYC | P01106 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535248 | 0.96 | MYC (0.39) | SCN9AMYCSCN5A | |
| SCHEMBL31535485 | 0.85 | ALDH1A1 (0.40) | SCN9AALDH1A1MAPT | |
| SCHEMBL31535400 | 0.81 | MYC (0.37) | MYCNPSR1ALDH1A1MAPT | |
| SCHEMBL31535253 | 0.77 | MYC (0.50) | SCN9AMYCALDH1A1 | |
| SCHEMBL31535281 | 0.77 | MYC (0.50) | SCN9AMYCALDH1A1 | |
| SCHEMBL31535503 | 0.77 | MYC (0.45) | SCN9AMYCALDH1A1 | |
| SCHEMBL31535450 | 0.77 | MYC (0.45) | SCN9AMYCALDH1A1 | |
| SCHEMBL31535341 | 0.76 | SCN9A (0.41) | SCN9ASCN5A | |
| SCHEMBL31535309 | 0.76 | MYC (0.52) | SCN9AMYCSCN5A | |
| SCHEMBL2433377 | 0.74 | ALDH1A1 (0.45) | MYCALDH1A1LCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | SCN9A 3184/4885MYC 358/4885SCN5A 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.